专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5710007A Methods for diagnosing prostatic adenocarcinoma 失效
标题翻译：诊断前列腺腺癌的方法
公开(公告)号：US5710007A
公开(公告)日：1998-01-20
申请号：US536215
申请日：1995-09-29
申请人： Albert A. Luderer , Grant D. Carlson , Ya-Ting Chen , Thomas F. Soriano , Robert P. Thiel
发明人： Albert A. Luderer , Grant D. Carlson , Ya-Ting Chen , Thomas F. Soriano , Robert P. Thiel
IPC分类号： G01N33/53 , G01N33/573 , G01N33/574 , G01N33/537 , G01N33/542
CPC分类号： G01N33/57488 , G01N33/57434
摘要： The present invention relates to a method for diagnosing prostatic adenocarcinoma (CAP) in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between 2.5 ng/ml and 20.0 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. If this proportion is less than about 7%, then the patient is diagnosed as having CAP. The present method can also be used on patients that have a total PSA of at least 10.1 ng/ml, but have also had a negative prostate biopsy.
摘要翻译：本发明涉及一种男性人类患者前列腺腺癌（CAP）诊断方法，无需进行活组织检查。测量患者血液或血清中的总前列腺特异性抗原（PSA）水平。如果患者的总PSA水平在2.5ng / ml和20.0ng / ml之间，则测量患者的血液或血清中的游离PSA水平。计算游离PSA与总PSA的比例。如果该比例小于约7％，那么患者被诊断为具有CAP。本方法也可用于总PSA至少为10.1ng / ml，但也具有阴性前列腺活检的患者。

2. 发明授权

US5698402A Methods for diagnosing benign prostatic hyperplasia 失效
标题翻译：诊断良性前列腺增生的方法
公开(公告)号：US5698402A
公开(公告)日：1997-12-16
申请号：US393214
申请日：1995-02-23
申请人： Albert A. Luderer , Grant D. Carlson , Robert P. Thiel , Thomas F. Soriano , William J. Kramp
发明人： Albert A. Luderer , Grant D. Carlson , Robert P. Thiel , Thomas F. Soriano , William J. Kramp
IPC分类号： G01N33/573 , G01N33/574 , G01N33/68
CPC分类号： G01N33/68 , G01N33/57434
摘要： The present invention relates to a method for diagnosing benign prostatic hyperplasia (BPH) in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between 2.5 ng/ml, (4.0 ng/ml for those 60 years or over), and 10.0 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. If this proportion is equal to or greater than about 25%, then the patient is diagnosed as having BPH.
摘要翻译：本发明涉及一种用于诊断男性人类患者的良性前列腺增生（BPH）的方法，而不需要活组织检查。测量患者血液或血清中的总前列腺特异性抗原（PSA）水平。如果患者的总PSA水平在2.5ng / ml之间（4.0ng / ml，60岁或以上）和10.0ng / ml，则测量患者血液或血清中的游离PSA水平。计算游离PSA与总PSA的比例。如果该比例等于或大于约25％，则患者被诊断为具有BPH。

3. 发明授权

US6100049A Methods for diagnosing benign prostatic diseases 失效
标题翻译：诊断良性前列腺疾病的方法
公开(公告)号：US6100049A
公开(公告)日：2000-08-08
申请号：US257407
申请日：1999-02-25
申请人： Albert A. Luderer , Grant D. Carlson , Robert P. Thiel , Thomas F. Soriano , William J. Kramp
发明人： Albert A. Luderer , Grant D. Carlson , Robert P. Thiel , Thomas F. Soriano , William J. Kramp
IPC分类号： G01N33/573 , G01N33/574 , G01N33/68
CPC分类号： G01N33/68 , G01N33/57434
摘要： The present invention relates to novel methods for diagnosing benign prostatic diseases (BPD), such as benign prostatic hyperplasia, prostatitis, or glandular atrophy, in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between about 2.5 ng/ml and 10.0 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. If this proportion is equal to or greater than about 25%, then the patient is diagnosed as having BPD. Optionally, if the patient has a total PSA level of between 10.1 ng/ml and 20.0 ng/ml, then the free PSA level in the blood or serum of the patient can also be measured. The proportion of free PSA to total PSA is calculated. If this proportion is equal to or greater than about 25%, then the patient is diagnosed as having BPD.
摘要翻译：本发明涉及在男性人类患者中诊断良性前列腺疾病（BPD），例如良性前列腺增生，前列腺炎或腺体萎缩的新方法，而不需要活组织检查。测量患者血液或血清中的总前列腺特异性抗原（PSA）水平。如果患者的总PSA水平在约2.5ng / ml至10.0ng / ml之间，则测量患者的血液或血清中的游离PSA水平。计算游离PSA与总PSA的比例。如果该比例等于或大于25％，那么患者被诊断为具有BPD。任选地，如果患者的总PSA水平在10.1ng / ml和20.0ng / ml之间，则也可以测量患者的血液或血清中的游离PSA水平。计算游离PSA与总PSA的比例。如果该比例等于或大于25％，那么患者被诊断为具有BPD。

4. 发明授权

US5912135A Methods for diagnosing benign prostatic diseases 失效
公开(公告)号：US5912135A
公开(公告)日：1999-06-15
申请号：US604685
申请日：1996-02-21
申请人： Albert A. Luderer , Grant D. Carlson , Robert P. Thiel , Thomas F. Soriano , William J. Kramp
发明人： Albert A. Luderer , Grant D. Carlson , Robert P. Thiel , Thomas F. Soriano , William J. Kramp
IPC分类号： G01N33/573 , G01N33/574 , G01N33/68
CPC分类号： G01N33/68 , G01N33/57434
摘要： The present invention relates to novel methods for diagnosing benign prostatic diseases (BPD), such as benign prostatic hyperplasia, prostatitis, or glandular atrophy, in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between about 2.5 ng/ml and 10.0 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. If this proportion is equal to or greater than about 25%, then the patient is diagnosed as having BPD. Optionally, if the patient has a total PSA level of between 10.1 ng/ml and 20.0 ng/ml, then the free PSA level in the blood or serum of the patient can also be measured. The proportion of free PSA to total PSA is calculated. If this proportion is equal to or greater than about 25%, then the patient is diagnosed as having BPD.

5. 发明授权

US6140065A Methods for diagnosing benign prostatic diseases and prostatic adenocarcinoma using an algorithm 失效
标题翻译：使用算法诊断良性前列腺疾病和前列腺腺癌的方法
公开(公告)号：US6140065A
公开(公告)日：2000-10-31
申请号：US924667
申请日：1997-09-05
申请人： Grant D. Carlson , Christina Beth Cavallo-Calvanese
发明人： Grant D. Carlson , Christina Beth Cavallo-Calvanese
IPC分类号： G01N33/574 , A61B5/00 , G01N33/48
CPC分类号： G01N33/57434
摘要： The present invention relates to novel reflex methods for identifying a male human patient as suitable for diagnosis either benign prostatic diseases (BPD), (such as benign prostatic hyperplasia, prostatitis, or glandular atrophy), or prostatic adenocarcinoma (CAP) without requiring a biopsy. The method requires measuring two biochemical markers and knowing the patient age. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between 4.0 ng/mL and 20.0 ng/mL, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. The patient's age is noted, rounding down to an integral numbers of years. The two measured values and the age are entered into a particular identifying algorithm which is derived from a logistic regression model. If a value of greater than about 0.18 is generated from entering these values into the algorithm, then the patient is diagnosed as having CAP. If value of less than or equal to about 0.18 is generated from entering these values into the algorithm, then the patient is diagnosed as having BPD.
摘要翻译：本发明涉及用于鉴定男性人类患者适合于诊断良性前列腺疾病（BPD）（如良性前列腺增生症，前列腺炎或腺体萎缩）或前列腺腺癌（CAP））而不需要活检的新型反射方法。该方法需要测量两个生物化学标记并知道患者年龄。测量患者血液或血清中的总前列腺特异性抗原（PSA）水平。如果患者的总PSA水平在4.0ng / mL至20.0ng / mL之间，则测量患者血液或血清中的游离PSA水平。计算游离PSA与总PSA的比例。患者的年龄被注意到四舍五入到一整年。将两个测量值和年龄输入到从逻辑回归模型中导出的特定识别算法。如果通过将这些值输入到算法中产生大于约0.18的值，则将患者诊断为具有CAP。如果通过将这些值输入到算法中产生小于或等于约0.18的值，则诊断患者具有BPD。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式